Item 5.07. Submission of Matters to a Vote of Security Holders
At the Protagonist Therapeutics, Inc. (the "Company") 2021 Annual Meeting of
Stockholders (the "Annual Meeting") held on May 27, 2021, the stockholders voted
on the two proposals listed below. The proposals are described in detail in the
Company's definitive proxy statement for the Annual Meeting, filed with the
Securities and Exchange Commission on April 14, 2021. The results of the matters
voted upon at the meeting were:
Proposal 1 - To elect the three Class II directors named below to serve until
the 2024 Annual Meeting of Stockholders. Each of the three named nominees was so
elected, with the votes thereon at the Annual Meeting as follows:
Final Voting Results
Nominees For Withheld Broker Non-Votes
Sarah A. O'Dowd 38,323,022 306,101 2,984,809
William D. Waddill 34,282,286 4,346,837 2,984,809
Lewis T. "Rusty" Williams, M.D., Ph.D. 34,296,520 4,332,603 2,984,809
Proposal 2 - To ratify the selection by the Audit Committee of the Board of
Directors of the Company of Ernst & Young LLP as the Company's independent
registered public accounting firm for the fiscal year ending December 31, 2021.
This proposal was approved by the requisite vote, with the votes thereon at the
Annual Meeting as follows:
Final Voting Results
For Against Abstain Broker Non-Votes
41,608,911 4,897 124 -
No other matters were submitted for stockholder action.
© Edgar Online, source Glimpses